Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2022 - 11 - 14 save search
Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit
Published: 2022-11-14 (Crawled : 22:00) - globenewswire.com
LXRX | $1.655 1.53% 1.51% 3M
|
Health Technology
|
| O: 3.43%
H: 2.07%
C: -3.73%
lx9211 treatment trial therapeutics results benefits diabetic
Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update
Published: 2022-11-14 (Crawled : 21:00) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -4.62%
H: 9.62%
C: 0.08%
trial therapeutics financial update
INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease
Published: 2022-11-14 (Crawled : 14:00) - globenewswire.com
INMB | $8.33 -5.34% -5.64% 69K
|
Health Technology
|
| O: 5.07%
H: 1.52%
C: -5.33%
disease canada health trial alzheimer’s
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
Published: 2022-11-14 (Crawled : 13:00) - investor.assemblybio.com
ASMB | $13.64 2.33% 2.27% 11K
|
Health Technology
|
| O: 0.75%
H: 8.89%
C: 7.41%
abi-4334 trial
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
Published: 2022-11-14 (Crawled : 13:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: 7.91%
H: 5.56%
C: -0.07%
macular trial therapeutics molecular phase 1
SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia
Published: 2022-11-14 (Crawled : 13:00) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: -31.65%
H: 2.89%
C: -18.01%
sciences life leukemia trial update acute myeloid leukemia
CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled
Published: 2022-11-14 (Crawled : 12:20) - prnewswire.com
CTSO | $0.8026 0.2% 0.2% 46K
|
Health Technology
|
| O: 6.58%
H: 0.0%
C: -4.94%
trial milestone
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
Published: 2022-11-14 (Crawled : 12:20) - biospace.com/
KZR | $0.7875 -0.01% -0.01% 420K
|
Health Technology
|
| O: 0.13%
H: 8.13%
C: 4.46%
sciences lupus life trial positive results
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine
Published: 2022-11-14 (Crawled : 12:00) - globenewswire.com
STSA | $1.1 -0.9% -0.91% 0
|
Health Technology
|
| O: -82.05%
H: 0.0%
C: 0.0%
sts101 treatment pharmaceuticals topline trial migraine
PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial
Published: 2022-11-14 (Crawled : 12:00) - globenewswire.com
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: 23.21%
H: 7.97%
C: 2.32%
biotech trial response cancer phase 2
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2022-11-14 (Crawled : 12:00) - globenewswire.com
VRDN | $14.59 -3.76% -3.91% 1.5M
|
Health Care and Social Assistan...
|
| O: -2.49%
H: 6.5%
C: 1.6%
vrdn-001 ongoing thyroid disease eye trial positive phase 1
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years
Published: 2022-11-13 (Crawled : 00:00) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: -13.42%
H: 4.11%
C: -3.5%
children trial 100 achondroplasia
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.